Cogent Biosciences, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $31.59
- 52-Week Range
- $13.78 – $43.73
- Market Cap
- $5.38B
- P/E (TTM)
- —
- EPS (TTM)
- -2.16
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 11.39
- PEG Ratio
- —
- Return on Equity
- -109.74%
- Return on Assets
- -43.84%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 13.57
- Debt/Equity
- 0.46
- Total Debt
- $244.26M
- Free Cash Flow
- $-186.15M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $4.90B
Market Snapshot
About
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, particularly advanced systemic mastocytosis and other mast cell-related conditions. Headquartered in Waltham, Massachusetts, the company's lead product candidate is bezuclastinib, an oral tyrosine kinase inhibitor designed to inhibit KIT D816V, a mutation found in most patients with systemic mastocytosis. Cogent utilizes a precision medicine approach to identify and treat patients with specific genetic mutations. The company is advancing clinical development programs for both hematologic and solid tumor indications.